AstraZeneca Licenses Nicotinic Alzheimer’s Treatment From Targacept
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm aims to bring the tobacco spin-off’s developmental neuronal nicotinic receptor modulator TC-1734 to market for Alzheimer’s and other cognitive disorders.
You may also be interested in...
Targacept’s AstraZeneca Deal Down, Not Out
First Alzheimer’s Phase III results are not great, but partner wants to see more before deciding.
Targacept’s AstraZeneca Deal Down, Not Out
First Alzheimer’s Phase III results are not great, but partner wants to see more before deciding.
Targacept CEO J. Donald DeBethizy - An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
DeBethizy discusses the firm’s unique origins, its work with AstraZeneca and what’s ahead for the Raleigh, N.C.-based company.